Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CARGO Therapeutics
Firicabtagene autoleucel (firi-cel) is an autologous CAR T-cell therapy targeting CD22, a common B-cell antigen widely expressed in LBCL. This Phase 2 study is designed to evaluate the safety and the efficacy of firi-cel in patients with R/R LBCL that has progressed after CD19-directed CAR T-cell therapy. The study is designed to treat up to 123 patients with a single infusion of firi-cel.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged ≥18 years
Relapsed or refractory, histologically confirmed large B-cell lymphoma.
Must have relapsed or refractory diseae after last therapy.
For enrollment in cohort 1, patients must have previously received a CD19-directed CAR T-cell therapy
For enrollment in cohort 3, patients must have received at least two prior lines of therapy including a bispecific T-cel engaging antibody therapy.
Must have at least one radiographically measurable lesion.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematological, renal, and liver function
Willing and able to remain within 1 hour of the treating center for at least 4 weeks after infusion.
You may not be if
Clinically significant concurrent medical illness
Active fungal, bacterial, viral or other infection.
Prior allogeneic stem cell transplant or allogeneic cell therapy
